Orlando 2025

INNOVATORS POP-UP HAVANA NIGHTS
October 16, 2025
Cuba Libre Restaurant & Rub Bar

INNOVATORS POP-UP HAVANA NIGHTS
October 16, 2025
Cuba Libre Restaurant & Rub Bar

What. a. Night.

Thank you to everyone who joined us for Innovators Pop-Up: Havana Nights! With nearly 300 attendees, the evening was buzzing with creativity, connection and the unmistakable spirit of innovation. A huge thank-you to our Innovation Partner and Sponsors for helping make this unforgettable evening possible.

We’re also celebrating our incredible Showcase Innovators who took the spotlight with bold ideas and breakthrough technologies advancing the future of eye health.

After an evening of rapid-fire pitches, powerful storytelling, and game-changing innovation, one company rose to the top…

Congratulations to Sydnexis, our 2025 Innovator of the Night!

People’s Choice Award

The people have spoken. 

After an incredible response from our community, we’re proud to announce the 2025 People’s Choice Award winner: eyejourney by Innoptix!

Selected by popular vote, this recognition celebrates innovation that truly resonated — highlighting creativity, impact, and the potential to shape the future of eye care.

Watch the winning video below and see why eyejourney by Innoptix earned the People’s Choice Award.

Thank you to everyone who participated, voted, and helped spotlight the innovators driving what’s next.

SHOWCASED INNOVATORS

Innovation Partner

SPONSORS

Event Album

Relive the night! Browse our event gallery filled with unforgettable moments, connections, and Havana-inspired energy.

EyeCool Therapeutics

EyeCool is developing a revolutionary treatment for Chronic Ocular Surface Pain (COSP). Our device is designed to deliver a targeted, precise dose of thermal energy to transform the experience of COSP patients.

eyejourney by Innoptix

eyejourney by Innoptix streamlines the patient journey by automating reminders, checklists, and medication tracking, improving patient engagement while delivering valuable benefits for clinics.

GreenMan Vision, Inc.

At Greenman, we are transforming cataract education using cutting edge technology. By turning complex medical decisions into clear, experience-driven choices, we’re empowering patients to take control of their vision health with confidence and strengthening surgeon-patient communication by fostering informed dialogue.

Our virtual reality technology, the InSightVR system, allows patients to visualize their post-surgical outcomes before making a decision. This sets realistic expectations, improves decision-making, and fosters trust.

Sydnexis

Sydnexis is a a privately-held, clinical stage biopharmaceutical company based in San Diego. Sydnexis is currently awaiting PDUFA approval at FDA for its patented eyedrop formulation, SYD-101, a low-dose atropine eye drop engineered specifically for growing eyes. It is being studied in children as young as 3 as a potential pharmaceutical treatment for progressive pediatric myopia. Our landmark STAR study — the largest and most comprehensive of its kind — has generated rigorous long-term data to help establish a safe, consistent solution to one of the most urgent unmet needs in pediatric ophthalmology.

TECLens

At TECLens, we’re dedicated to restoring vision and improving quality of life for millions of people around the world.

Our innovative treatment utilizes proprietary quantitative corneal cross-linking (qCXL™) technology and the CXLens® device to gently strengthen and reshape the cornea, designed to redefine vision correction for refractive errors, including restoring near vision for those with presbyopia. The procedure aims to be a comfortable, non-invasive, in-office treatments.

TECLens is also exploring future applications for hyperopia, progressive myopia in children and low-order myopia in adults, and keratoconus, promising a brighter future for vision correction.

Osheru

Osheru is a medical device company that is innovating skin removal with a new technology-compressive skin contouring. Our initial product, the Ziplyft, revolutionizes blepharoplasty (eyelid) surgery by making it faster and easier on the patient and the surgeon without the need for cautery or sutures. The patient benefits by having less bruising and downtime and the surgeon benefits by having an efficient and consistent procedure.

Visionary Ventures

Visionary Ventures is a venture capital fund that partners with KOLs to invest in life sciences and the future of ophthalmology. We are an opportunistic venture fund that invests in early and late stages of a company’s growth, from early-stage Series A rounds in clinical trials to late-stage rounds in commercialization. Our target investment range is $5M to $15M.

Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.

True North

True North Contract Research is a dynamic and rapidly growing Contract Research Organization (CRO) specializing in Ophthalmology research. We strive to deliver an experience that is second to none to our sponsor partners and site partners. Our longstanding commitment to advancing the field of ophthalmology through clinical research has provided us with the experience to execute trials efficiently with a focus on accuracy and compliance. We merge FDA and clinical site perspectives to identify effective solutions that are agreeable to both parties and then mitigate roadblocks to achieve trial endpoints. One of our greatest strengths is uniting with sponsoring companies as a seamless team that makes well-thought-through decisions on time.

Amaros

BIO

Amaros’ EvidenceEngine™ is an AI-powered platform designed to unify and transform fragmented ophthalmic data into actionable intelligence, revolutionizing clinical development, research, and therapeutic decision-making across the eye care continuum. Built in Silicon Valley and backed by serial ophthalmic entrepreneurs, AI scientists, clinicians, and CRO experts, the platform targets a critical bottleneck in ophthalmology: disconnected datasets that hinder efficient trials, slow adoption of therapies, and limit patient access.